ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts | Fierce Biotech
Mosunetuzumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Raul Cordoba, MD, PhD on Twitter: "#ASH19 Mosunetuzumab induces CR in poor prognosis NHL patients including those who are resistant to or relapsing after #CART therapies #lymsm. Data coming from the first
FDA approves Genentech's Lunsumio - Medical Buyer
ASH 2022: Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Roche reveals new bispecific antibody data in blood cancers - PharmaTimes
PDF) An individualized risk mitigation approach for safety: experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk.
LUNSUMIO™ (mosunetuzumab-axgb) Clinical Trial | HCP
Roche antibody posts strong tumor responses in lymphoma study
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
Mosunetuzumab: First Approval
PATIENTENPASS
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - The Lancet Oncology
Robust clinical data on Roche 3 bispecific antibodies was released- Mosunetuzumab, Glofitamab, and Cevostamab! : r/medical_trend
CHMP backs Roche's lymphoma bispecific mosunetuzumab | pharmaphorum
Roche presents latest advances with immunotherapies in non-Hodgkin lym
Mosunetuzumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
CHMP recommends EU conditional approval of Roche's antibody Mosunetuzumab for people with relapsed Follicular Lymphoma - Express Pharma
로슈, 'CD20xCD3' 이중항체 림프종 1/2상 “CR 60%” - 바이오스펙테이터
IJMS | Free Full-Text | Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
Mosunetuzumab shows deep, durable responses in advanced follicular lymphoma
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study - The Lancet Oncology
